Skip to main content
Frederick Beddingfield, MD, Dermatology, Los Angeles, CA

FrederickCostonBeddingfieldMDPhD

Dermatology • Los Angeles, CA

Assistant Clinical Professor, Dermatology, UCLA School of Medicine

Join to view full profile

Dr. Beddingfield is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Beddingfield's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1998 - 2001
  • Los Angeles County-Harbor-UCLA Medical Center
    Los Angeles County-Harbor-UCLA Medical CenterResidency, Emergency Medicine, 1991 - 1995
  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1992 - 2024
  • CO State Medical License
    CO State Medical License 1995 - 1999
  • American Board of Dermatology Dermatology

Awards, Honors, & Recognition

  • Fellow (FASDS) American Society for Dermatologic Surgery

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Myth Busters: A Critical Evaluation of the Evidence Behind Common Cosmetic Recommendations 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

  • Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)November 30th, 2022
  • Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
    Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal HemoglobinuriaJuly 28th, 2022
  • Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
    Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, ChinaFebruary 23rd, 2021
  • Join now to see all

Professional Memberships

Dr. Frederick Beddingfield, Dr. Frederick Beddingfield, MD, Dr. F Beddingfield, Dr. Frederick Coston Beddingfield